MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-10-2026
Homology Medicines Operating Income 2011-2026 | FIXX
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Homology Medicines
| 2025 | 2024 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 16.9 M | -66.1 M | -133 M | -95.9 M | -130 M | -110 M | -59.9 M | -29.7 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 16.9 M | -133 M | -76 M |
Quarterly Operating Income Homology Medicines
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -7.58 M | -9.17 M | -12.2 M | - | -18.8 M | -17.9 M | -14.8 M | - | -7.8 M | -7.28 M | -27.5 M | - | -32.9 M | -28.3 M | -37.6 M | - | -30.7 M | -30.6 M | -1.11 M | - | -28.3 M | -35.7 M | -36.5 M | - | -31.3 M | -28 M | -25.1 M | - | -59.9 M | -59.9 M | -59.9 M | - | -6.66 M | -6.04 M | -4.69 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -1.11 M | -59.9 M | -24.7 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M |  Germany |
 |
Genfit SA
GNFT
|
31.8 M | - | 2.54 % | $ 160 B |  France |
 |
Autolus Therapeutics plc
AUTL
|
-271 M | $ 1.34 | -3.6 % | $ 357 M |  Britain |
 |
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M | France |
 |
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Acorda Therapeutics
ACOR
|
-265 M | - | -24.86 % | $ 820 K |  USA |
 |
DBV Technologies S.A.
DBVT
|
-147 M | $ 20.13 | -1.13 % | $ 2.81 B | France |
 |
Advaxis
ADXS
|
-36.3 M | - | -9.65 % | $ 45.9 M | USA |
 |
Dyadic International
DYAI
|
-7.19 M | $ 0.87 | - | $ 31.5 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-139 M | - | - | $ 86.2 M | USA |
 |
Aytu BioScience
AYTU
|
-7.83 M | $ 2.57 | -3.57 % | $ 16.1 M | USA |
 |
Equillium
EQ
|
-23.6 M | $ 2.04 | 1.24 % | $ 117 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-24 M | - | -10.17 % | $ 12.2 K | USA |
 |
Fate Therapeutics
FATE
|
-148 M | $ 1.13 | -5.04 % | $ 134 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-210 M | - | - | $ 1.01 B | USA |
 |
Forte Biosciences
FBRX
|
-70.7 M | $ 26.57 | 0.49 % | $ 344 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-17.7 M | - | - | $ 26.5 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
-6.28 M | $ 6.14 | -4.36 % | $ 175 M | USA |
|
Foghorn Therapeutics
FHTX
|
-86.4 M | $ 4.74 | -2.87 % | $ 299 M | USA |
 |
AIkido Pharma
AIKI
|
-55.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Amicus Therapeutics
FOLD
|
32.8 M | $ 14.46 | 0.03 % | $ 4.46 B | USA |
 |
Fulcrum Therapeutics
FULC
|
-84.8 M | $ 7.55 | -3.58 % | $ 478 K | USA |
 |
Galectin Therapeutics
GALT
|
-20.1 M | $ 2.25 | -12.3 % | $ 144 M | USA |
 |
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | USA |
 |
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | Germany |
 |
BioNTech SE
BNTX
|
15.3 B | $ 87.65 | -3.98 % | $ 27.2 B | Germany |
 |
Gilead Sciences
GILD
|
10 B | $ 138.19 | -1.38 % | $ 172 B | USA |
 |
Coherus BioSciences
CHRS
|
-181 M | $ 1.61 | -3.59 % | $ 189 M | USA |
 |
Akari Therapeutics, Plc
AKTX
|
-17.3 M | $ 3.5 | -1.13 % | $ 236 B | Britain |
 |
Akouos
AKUS
|
-86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
-30.2 M | $ 0.54 | 4.26 % | $ 503 K |  Israel |
 |
Genmab A/S
GMAB
|
2.64 B | $ 27.01 | -2.67 % | $ 17.2 B |  Danmark |
 |
Allakos
ALLK
|
-196 M | - | - | $ 28.6 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-47.6 M | - | 3.16 % | $ 1.9 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
502 M | $ 314.44 | -4.81 % | $ 41.2 B | USA |
 |
Gossamer Bio
GOSS
|
-171 M | $ 0.32 | -7.11 % | $ 73.1 M | USA |
 |
Grifols, S.A.
GRFS
|
595 M | $ 7.91 | -3.95 % | $ 6.83 B |  Spain |
 |
Alpine Immune Sciences
ALPN
|
-58.1 M | - | - | $ 2.17 B | USA |
 |
GT Biopharma
GTBP
|
-12.4 M | $ 0.42 | -6.49 % | $ 2.32 M | USA |
 |
Aileron Therapeutics
ALRN
|
-50.6 M | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
-46.2 M | - | 4.14 % | $ 49.1 M | USA |
 |
Halozyme Therapeutics
HALO
|
469 M | $ 63.51 | 0.68 % | $ 7.61 B | USA |
 |
Burford Capital Limited
BUR
|
242 M | $ 4.42 | -1.34 % | $ 727 M | Britain |